Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment. An international ...

Methicillin-resistant Staphylococcus epidermidis (MRSE) is a drug-resistant form of staph bacteria. MRSE infections may be difficult to treat due to their resistance to methicillin and other common ...

ZEVTERA is the first and only U.S. Food and Drug Administration-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia (SAB), including right-sided endocarditis, caused by the ...

Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025 LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (ARMP) ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...

There are plenty of infections that you get on a regular basis, such as a cold or a stomach bug, and don't even think twice. You do what you need to do to treat it and recover and you move on. But ...

Methicillin-resistant Staphylococcus aureus (MRSA) bacteria is often found in the skin folds. Less commonly, this includes the buttocks. Methicillin-resistant Staphylococcus aureus (MRSA) is a ...

Lincoln, Neb. — Researchers at the University of Nebraska–Lincoln are working to halt resistance to an antibiotic used to treat serious staph infections in humans. Staphylococcus aureus is a bacterium ...

LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific ...